Analyst consensus rating
Cartesian Therapeutics Analyst Rating: Strong Buy
RNAC is rated Strong Buy by 7 analysts with a $34.57 target. As of 2026-08-23.
Direct answer
Cartesian Therapeutics's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $34.57.
Forecast evidence checked August 23, 2026.
Get free Cartesian Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $10.04
- Average price target
- $34.57
- High price target
- $44.00
- Low price target
- $16.00
- Low target gap
- +59.4%
- Target upside
- +244.3%
- High target gap
- +338.2%
- Target range width
- 278.9%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cartesian Therapeutics?
Cartesian Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $34.57.
How far are Cartesian Therapeutics's low and high targets from the recorded price?
The low target implies +59.4%, while the high target implies +338.2%.
How many analysts are included in Cartesian Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is Cartesian Therapeutics's target upside or downside calculated?
The average target of $34.57 is divided by the recorded price of $10.04, then one is subtracted to produce +244.3%. This does not guarantee a future return.
When was Cartesian Therapeutics's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.